Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies
Abstract
:1. Introduction
2. Advanced Glycation End Products
2.1. AGEs Formation
2.2. Characteristics of AGEs
2.3. AGEs Measurements
3. Dietary Patterns Influence on Carbonyl Stress or Blood AGEs Levels
4. Dietary AGEs Influence on Glucose Homeostasis
5. Dietary AGEs Influence on Body Weight
6. Dietary AGEs Influence on Oxidative Stress and Inflammation
7. Dietary AGEs Influence on Vascular Function
8. Dietary AGEs Influence on Gut Microbiome
9. Skin AGEs as a Predictor of Cardiometabolic Disorders
10. Conclusions
Funding
Conflicts of Interest
References
- Yozgatli, K.; Lefrandt, J.D.; Noordzij, M.J.; Oomen, P.H.N.; Brouwer, T.; Jager, J.; Castro Cabezas, M.; Smit, A.J. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. Diabet. Med. A J. Br. Diabet. Assoc. 2018; Online ahead of print. [Google Scholar] [CrossRef]
- Tan, K.C.; Shiu, S.W.; Wong, Y.; Tam, X. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes/Metab. Res. Rev. 2011, 27, 488–492. [Google Scholar] [CrossRef] [PubMed]
- Tahara, N.; Yamagishi, S.; Matsui, T.; Takeuchi, M.; Nitta, Y.; Kodama, N.; Mizoguchi, M.; Imaizumi, T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc. Ther. 2012, 30, 42–48. [Google Scholar] [CrossRef]
- Sebeková, K.; Krivošíková, Z.; Gajdoš, M. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clin. Chem. Lab. Med. 2014, 52, 139–149. [Google Scholar] [CrossRef]
- Accacha, S.; Rosenfeld, W.; Jacobson, A.; Michel, L.; Schnurr, F.J.; Shelov, S.; Ten, S.; Boucher-Berry, C.; Carey, D.E.; Speiser, P.W.; et al. Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children. Horm. Res. Paediatr. 2013, 80, 318–327. [Google Scholar] [CrossRef] [PubMed]
- Sebeková, K.; Somoza, V.; Jarcusková, M.; Heidland, A.; Podracká, L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int. J. Pediatr. Obes. IJPO Off. J. Int. Assoc. Study Obes. 2009, 4, 112–118. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Huang, Q.; Liu, W.; Zhou, X. Advanced glycation end products via skin autofluorescence as a new biomarker for major adverse cardiovascular events: A meta-analysis of prospective studies. Nutr. Metab. Cardiovasc. Dis. NMCD 2022, 32, 1083–1092. [Google Scholar] [CrossRef]
- Clarke, R.E.; Dordevic, A.L.; Tan, S.M.; Ryan, L.; Coughlan, M.T. Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials. Nutrients 2016, 8, 125. [Google Scholar] [CrossRef]
- Luévano-Contreras, C.; Gómez-Ojeda, A.; Macías-Cervantes, M.H.; Garay-Sevilla, M.E. Dietary Advanced Glycation End Products and Cardiometabolic Risk. Curr. Diabetes Rep. 2017, 17, 63. [Google Scholar] [CrossRef]
- Cai, W.; He, J.C.; Zhu, L.; Peppa, M.; Lu, C.; Uribarri, J.; Vlassara, H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110, 285–291. [Google Scholar] [CrossRef]
- Harcourt, B.E.; Sourris, K.C.; Coughlan, M.T.; Walker, K.Z.; Dougherty, S.L.; Andrikopoulos, S.; Morley, A.L.; Thallas-Bonke, V.; Chand, V.; Penfold, S.A.; et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011, 80, 190–198. [Google Scholar] [CrossRef]
- Luévano-Contreras, C.; Garay-Sevilla, M.E.; Wrobel, K.; Malacara, J.M.; Wrobel, K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J. Clin. Biochem. Nutr. 2013, 52, 22–26. [Google Scholar] [CrossRef]
- Mark, A.B.; Poulsen, M.W.; Andersen, S.; Andersen, J.M.; Bak, M.J.; Ritz, C.; Holst, J.J.; Nielsen, J.; de Courten, B.; Dragsted, L.O.; et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014, 37, 88–95. [Google Scholar] [CrossRef]
- Peppa, M.; Uribarri, J.; Cai, W.; Lu, M.; Vlassara, H. Glycoxidation and inflammation in renal failure patients. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2004, 43, 690–695. [Google Scholar] [CrossRef] [PubMed]
- Semba, R.D.; Gebauer, S.K.; Baer, D.J.; Sun, K.; Turner, R.; Silber, H.A.; Talegawkar, S.; Ferrucci, L.; Novotny, J.A. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J. Nutr. 2014, 144, 1037–1042. [Google Scholar] [CrossRef] [PubMed]
- Uribarri, J.; Cai, W.; Pyzik, R.; Goodman, S.; Chen, X.; Zhu, L.; Ramdas, M.; Striker, G.E.; Vlassara, H. Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 2014, 46, 301–309. [Google Scholar] [CrossRef] [PubMed]
- Uribarri, J.; Cai, W.; Ramdas, M.; Goodman, S.; Pyzik, R.; Chen, X.; Zhu, L.; Striker, G.E.; Vlassara, H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 2011, 34, 1610–1616. [Google Scholar] [CrossRef]
- Uribarri, J.; Peppa, M.; Cai, W.; Goldberg, T.; Lu, M.; Baliga, S.; Vassalotti, J.A.; Vlassara, H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2003, 42, 532–538. [Google Scholar] [CrossRef]
- Vlassara, H.; Cai, W.; Crandall, J.; Goldberg, T.; Oberstein, R.; Dardaine, V.; Peppa, M.; Rayfield, E.J. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. USA 2002, 99, 15596–15601. [Google Scholar] [CrossRef]
- Vlassara, H.; Cai, W.; Goodman, S.; Pyzik, R.; Yong, A.; Chen, X.; Zhu, L.; Neade, T.; Beeri, M.; Silverman, J.M.; et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 2009, 94, 4483–4491. [Google Scholar] [CrossRef]
- John, W.G.; Lamb, E.J. The Maillard or browning reaction in diabetes. Eye 1993, 7 Pt 2, 230–237. [Google Scholar] [CrossRef]
- Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: A review. Diabetologia 2001, 44, 129–146. [Google Scholar] [CrossRef]
- Garay-Sevilla, M.E.; Rojas, A.; Portero-Otin, M.; Uribarri, J. Dietary AGEs as Exogenous Boosters of Inflammation. Nutrients 2021, 13, 2802. [Google Scholar] [CrossRef]
- Uribarri, J.; Woodruff, S.; Goodman, S.; Cai, W.; Chen, X.; Pyzik, R.; Yong, A.; Striker, G.E.; Vlassara, H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 2010, 110, 911–916. [Google Scholar] [CrossRef] [PubMed]
- Cerami, C.; Founds, H.; Nicholl, I.; Mitsuhashi, T.; Giordano, D.; Vanpatten, S.; Lee, A.; Al-Abed, Y.; Vlassara, H.; Bucala, R.; et al. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. USA 1997, 94, 13915–13920. [Google Scholar] [CrossRef]
- Nicholl, I.D.; Bucala, R. Advanced glycation endproducts and cigarette smoking. Cell. Mol. Biol. 1998, 44, 1025–1033. [Google Scholar] [PubMed]
- Inan-Eroglu, E.; Ayaz, A.; Buyuktuncer, Z. Formation of advanced glycation endproducts in foods during cooking process and underlying mechanisms: A comprehensive review of experimental studies. Nutr. Res. Rev. 2020, 33, 77–89. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, J.; Morrissey, P.A. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr. 1989, 28, 211–248. [Google Scholar] [CrossRef]
- Goldberg, T.; Cai, W.; Peppa, M.; Dardaine, V.; Baliga, B.S.; Uribarri, J.; Vlassara, H. Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc. 2004, 104, 1287–1291. [Google Scholar] [CrossRef]
- Scheijen, J.; Clevers, E.; Engelen, L.; Dagnelie, P.C.; Brouns, F.; Stehouwer, C.D.A.; Schalkwijk, C.G. Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database. Food Chem. 2016, 190, 1145–1150. [Google Scholar] [CrossRef]
- Thornalley, P.J. Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification—A role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 1996, 27, 565–573. [Google Scholar] [CrossRef]
- Henning, C.; Glomb, M.A. Pathways of the Maillard reaction under physiological conditions. Glycoconj. J. 2016, 33, 499–512. [Google Scholar] [CrossRef] [PubMed]
- Hamada, Y.; Araki, N.; Koh, N.; Nakamura, J.; Horiuchi, S.; Hotta, N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Commun. 1996, 228, 539–543. [Google Scholar] [CrossRef] [PubMed]
- Twarda-Clapa, A.; Olczak, A.; Białkowska, A.M.; Koziołkiewicz, M. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells 2022, 11, 1312. [Google Scholar] [CrossRef] [PubMed]
- Khalid, M.; Petroianu, G.; Adem, A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules 2022, 12, 542. [Google Scholar] [CrossRef]
- Chung, S.S.; Ho, E.C.; Lam, K.S.; Chung, S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. JASN 2003, 14, S233–S236. [Google Scholar] [CrossRef]
- Fiorentino, T.V.; Prioletta, A.; Zuo, P.; Folli, F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr. Pharm. Des. 2013, 19, 5695–5703. [Google Scholar] [CrossRef]
- Dias, I.H.; Griffiths, H.R. Oxidative stress in diabetes—Circulating advanced glycation end products, lipid oxidation and vascular disease. Ann. Clin. Biochem. 2014, 51, 125–127. [Google Scholar] [CrossRef]
- Moldogazieva, N.T.; Mokhosoev, I.M.; Mel’nikova, T.I.; Porozov, Y.B.; Terentiev, A.A. Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases. Oxidative Med. Cell. Longev. 2019, 2019, 3085756. [Google Scholar] [CrossRef]
- Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014, 2, 411–429. [Google Scholar] [CrossRef]
- Thornalley, P.J.; Langborg, A.; Minhas, H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344 Pt 1, 109–116. [Google Scholar] [CrossRef]
- Fu, M.X.; Requena, J.R.; Jenkins, A.J.; Lyons, T.J.; Baynes, J.W.; Thorpe, S.R. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 1996, 271, 9982–9986. [Google Scholar] [CrossRef] [PubMed]
- Kamalvand, G.; Ali-Khan, Z. Immunolocalization of lipid peroxidation/advanced glycation end products in amyloid A amyloidosis. Free Radic. Biol. Med. 2004, 36, 657–664. [Google Scholar] [CrossRef] [PubMed]
- Gerdemann, A.; Lemke, H.D.; Nothdurft, A.; Heidland, A.; Münch, G.; Bahner, U.; Schinzel, R. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin. Nephrol. 2000, 54, 276–283. [Google Scholar] [PubMed]
- Thomas, M.C.; Forbes, J.M.; MacIsaac, R.; Jerums, G.; Cooper, M.E. Low-molecular weight advanced glycation end products: Markers of tissue AGE accumulation and more? Ann. N. Y. Acad. Sci. 2005, 1043, 644–654. [Google Scholar] [CrossRef]
- Manig, F.; Hellwig, M.; Pietz, F.; Henle, T. Studies about the Dietary Impact on “Free” Glycation Compounds in Human Saliva. Foods 2022, 11, 2112. [Google Scholar] [CrossRef]
- Hellwig, M.; Geissler, S.; Matthes, R.; Peto, A.; Silow, C.; Brandsch, M.; Henle, T. Transport of free and peptide-bound glycated amino acids: Synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins. Chembiochem A Eur. J. Chem. Biol. 2011, 12, 1270–1279. [Google Scholar] [CrossRef]
- Scheijen, J.; Hanssen, N.M.J.; van Greevenbroek, M.M.; Van der Kallen, C.J.; Feskens, E.J.M.; Stehouwer, C.D.A.; Schalkwijk, C.G. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: The CODAM study. Clin. Nutr. 2018, 37, 919–925. [Google Scholar] [CrossRef]
- Willemsen, S.; Hartog, J.W.; Heiner-Fokkema, M.R.; van Veldhuisen, D.J.; Voors, A.A. Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail. Rev. 2012, 17, 221–228. [Google Scholar] [CrossRef]
- Cavero-Redondo, I.; Soriano-Cano, A.; Álvarez-Bueno, C.; Cunha, P.G.; Martínez-Hortelano, J.A.; Garrido-Miguel, M.; Berlanga-Macías, C.; Martínez-Vizcaíno, V. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. J. Am. Heart Assoc. 2018, 7, e009833. [Google Scholar] [CrossRef]
- Bakris, G.L.; Bank, A.J.; Kass, D.A.; Neutel, J.M.; Preston, R.A.; Oparil, S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 2004, 17, 23s–30s. [Google Scholar] [CrossRef]
- Nagai, R.; Murray, D.B.; Metz, T.O.; Baynes, J.W. Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012, 61, 549–559. [Google Scholar] [CrossRef] [PubMed]
- Reddy, V.P.; Beyaz, A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov. Today 2006, 11, 646–654. [Google Scholar] [CrossRef]
- Voziyan, P.A.; Khalifah, R.G.; Thibaudeau, C.; Yildiz, A.; Jacob, J.; Serianni, A.S.; Hudson, B.G. Modification of proteins in vitro by physiological levels of glucose: Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 2003, 278, 46616–46624. [Google Scholar] [CrossRef] [PubMed]
- Candido, R.; Forbes, J.M.; Thomas, M.C.; Thallas, V.; Dean, R.G.; Burns, W.C.; Tikellis, C.; Ritchie, R.H.; Twigg, S.M.; Cooper, M.E.; et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 2003, 92, 785–792. [Google Scholar] [CrossRef] [PubMed]
- Wu, X.; Monnier, V.M. Enzymatic deglycation of proteins. Arch. Biochem. Biophys. 2003, 419, 16–24. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, Y.; Yamagishi, S.; Matsui, T.; Ohta, K.; Tanoue, R.; Takeuchi, M.; Ueda, S.; Nakamura, K.; Okuda, S. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metab. Clin. Exp. 2012, 61, 1067–1072. [Google Scholar] [CrossRef] [PubMed]
- Miyata, T.; van Ypersele de Strihou, C.; Ueda, Y.; Ichimori, K.; Inagi, R.; Onogi, H.; Ishikawa, N.; Nangaku, M.; Kurokawa, K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J. Am. Soc. Nephrol. JASN 2002, 13, 2478–2487. [Google Scholar] [CrossRef]
- Mustata, G.T.; Rosca, M.; Biemel, K.M.; Reihl, O.; Smith, M.A.; Viswanathan, A.; Strauch, C.; Du, Y.; Tang, J.; Kern, T.S.; et al. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: Improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005, 54, 517–526. [Google Scholar] [CrossRef]
- Bronowicka-Szydełko, A.; Krzystek-Korpacka, M.; Gacka, M.; Pietkiewicz, J.; Jakobsche-Policht, U.; Gamian, A. Association of Novel Advanced Glycation End-Product (AGE10) with Complications of Diabetes as Measured by Enzyme-Linked Immunosorbent Assay. J. Clin. Med. 2021, 10, 4499. [Google Scholar] [CrossRef]
- Nakayama, H.; Makita, Z.; Kato, M.; Taneda, S.; Yoshida, H.; Yanagisawa, K.; Nakagawa, S. Quantitative enzyme-linked immunosorbent assay (ELISA) for non-enzymatically glycated serum protein. J. Immunol. Methods 1987, 99, 95–100. [Google Scholar] [CrossRef]
- Maciel, E.; da Silva, R.N.; Simões, C.; Melo, T.; Ferreira, R.; Domingues, P.; Domingues, M.R. Liquid chromatography-tandem mass spectrometry of phosphatidylserine advanced glycated end products. Chem. Phys. Lipids 2013, 174, 1–7. [Google Scholar] [CrossRef]
- Nagai, R.; Shirakawa, J.; Ohno, R.; Hatano, K.; Sugawa, H.; Arakawa, S.; Ichimaru, K.; Kinoshita, S.; Sakata, N.; Nagai, M. Antibody-based detection of advanced glycation end-products: Promises vs. limitations. Glycoconj. J. 2016, 33, 545–552. [Google Scholar] [CrossRef] [PubMed]
- Milkovska-Stamenova, S.; Schmidt, R.; Frolov, A.; Birkemeyer, C. GC-MS Method for the Quantitation of Carbohydrate Intermediates in Glycation Systems. J. Agric. Food Chem. 2015, 63, 5911–5919. [Google Scholar] [CrossRef] [PubMed]
- Meerwaldt, R.; Links, T.; Graaff, R.; Thorpe, S.R.; Baynes, J.W.; Hartog, J.; Gans, R.; Smit, A. Simple noninvasive measurement of skin autofluorescence. Ann. N. Y. Acad. Sci. 2005, 1043, 290–298. [Google Scholar] [CrossRef]
- Mulder, D.J.; Water, T.V.; Lutgers, H.L.; Graaff, R.; Gans, R.O.; Zijlstra, F.; Smit, A.J. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technol. Ther. 2006, 8, 523–535. [Google Scholar] [CrossRef] [PubMed]
- Larsson, M.; Favilla, R.; Strömberg, T. Assessment of advanced glycated end product accumulation in skin using auto fluorescence multispectral imaging. Comput. Biol. Med. 2017, 85, 106–111. [Google Scholar] [CrossRef] [PubMed]
- Maasen, K.; van Greevenbroek, M.M.J.; Scheijen, J.; van der Kallen, C.J.H.; Stehouwer, C.D.A.; Schalkwijk, C.G. High dietary glycemic load is associated with higher concentrations of urinary advanced glycation endproducts: The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study. Am. J. Clin. Nutr. 2019, 110, 358–366. [Google Scholar] [CrossRef]
- Delgado-Andrade, C.; Tessier, F.J.; Niquet-Leridon, C.; Seiquer, I.; Pilar Navarro, M. Study of the urinary and faecal excretion of Nε-carboxymethyllysine in young human volunteers. Amino Acids 2012, 43, 595–602. [Google Scholar] [CrossRef]
- Brinkley, T.E.; Semba, R.D.; Kritchevsky, S.B.; Houston, D.K. Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study. Am. J. Clin. Nutr. 2020, 112, 1558–1565. [Google Scholar] [CrossRef]
- Davis, C.; Bryan, J.; Hodgson, J.; Murphy, K. Definition of the Mediterranean Diet; a Literature Review. Nutrients 2015, 7, 9139–9153. [Google Scholar] [CrossRef]
- Morris, L.; Bhatnagar, D. The Mediterranean diet. Curr. Opin. Lipidol. 2016, 27, 89–91. [Google Scholar] [CrossRef]
- Gerrits, E.G.; Lutgers, H.L.; Smeets, G.H.; Groenier, K.H.; Smit, A.J.; Gans, R.O.; Bilo, H.J. Skin autofluorescence: A pronounced marker of mortality in hemodialysis patients. Nephron Extra 2012, 2, 184–191. [Google Scholar] [CrossRef] [PubMed]
- Lopez-Moreno, J.; Quintana-Navarro, G.M.; Delgado-Lista, J.; Garcia-Rios, A.; Delgado-Casado, N.; Camargo, A.; Perez-Martinez, P.; Striker, G.E.; Tinahones, F.J.; Perez-Jimenez, F.; et al. Mediterranean Diet Reduces Serum Advanced Glycation End Products and Increases Antioxidant Defenses in Elderly Adults: A Randomized Controlled Trial. J. Am. Geriatr. Soc. 2016, 64, 901–904. [Google Scholar] [CrossRef] [PubMed]
- Lopez-Moreno, J.; Quintana-Navarro, G.M.; Camargo, A.; Jimenez-Lucena, R.; Delgado-Lista, J.; Marin, C.; Tinahones, F.J.; Striker, G.E.; Roche, H.M.; Perez-Martinez, P.; et al. Dietary fat quantity and quality modifies advanced glycation end products metabolism in patients with metabolic syndrome. Mol. Nutr. Food Res. 2017, 61, 1601029. [Google Scholar] [CrossRef] [PubMed]
- Nowotny, K.; Jung, T.; Höhn, A.; Weber, D.; Grune, T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015, 5, 194–222. [Google Scholar] [CrossRef] [PubMed]
- Uribarri, J.; Cai, W.; Woodward, M.; Tripp, E.; Goldberg, L.; Pyzik, R.; Yee, K.; Tansman, L.; Chen, X.; Mani, V.; et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: A link between healthy and unhealthy obesity? J. Clin. Endocrinol. Metab. 2015, 100, 1957–1966. [Google Scholar] [CrossRef]
- Poulsen, M.W.; Bak, M.J.; Andersen, J.M.; Monošík, R.; Giraudi-Futin, A.C.; Holst, J.J.; Nielsen, J.; Lauritzen, L.; Larsen, L.H.; Bügel, S.; et al. Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endothelial activation in healthy overweight individuals. Eur. J. Nutr. 2014, 53, 661–672. [Google Scholar] [CrossRef]
- Schiekofer, S.; Franke, S.; Andrassy, M.; Chen, J.; Rudofsky, G.; Schneider, J.G.; von Eynatten, M.; Wendt, T.; Morcos, M.; Kientsch-Engel, R.; et al. Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal. Exp. Clin. Endocrinol. Diabetes 2006, 114, 160–167. [Google Scholar] [CrossRef]
- Negrean, M.; Stirban, A.; Stratmann, B.; Gawlowski, T.; Horstmann, T.; Götting, C.; Kleesiek, K.; Mueller-Roesel, M.; Koschinsky, T.; Uribarri, J.; et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am. J. Clin. Nutr. 2007, 85, 1236–1243. [Google Scholar] [CrossRef]
- Sohouli, M.H.; Fatahi, S.; Sharifi-Zahabi, E.; Santos, H.O.; Tripathi, N.; Lari, A.; Pourrajab, B.; Kord-Varkaneh, H.; Găman, M.A.; Shidfar, F. The Impact of Low Advanced Glycation End Products Diet on Metabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv. Nutr. 2021, 12, 766–776. [Google Scholar] [CrossRef]
- Baye, E.; Kiriakova, V.; Uribarri, J.; Moran, L.J.; de Courten, B. Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: Meta-analysis of randomised controlled trials. Sci. Rep. 2017, 7, 2266. [Google Scholar] [CrossRef]
- Vlassara, H.; Cai, W.; Tripp, E.; Pyzik, R.; Yee, K.; Goldberg, L.; Tansman, L.; Chen, X.; Mani, V.; Fayad, Z.A.; et al. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: A randomised controlled trial. Diabetologia 2016, 59, 2181–2192. [Google Scholar] [CrossRef] [PubMed]
- Di Pino, A.; Currenti, W.; Urbano, F.; Mantegna, C.; Purrazzo, G.; Piro, S.; Purrello, F.; Rabuazzo, A.M. Low advanced glycation end product diet improves the lipid and inflammatory profiles of prediabetic subjects. J. Clin. Lipidol. 2016, 10, 1098–1108. [Google Scholar] [CrossRef] [PubMed]
- Baye, E.; de Courten, M.P.; Walker, K.; Ranasinha, S.; Earnest, A.; Forbes, J.M.; de Courten, B. Effect of dietary advanced glycation end products on inflammation and cardiovascular risks in healthy overweight adults: A randomised crossover trial. Sci. Rep. 2017, 7, 4123. [Google Scholar] [CrossRef] [PubMed]
- Macías-Cervantes, M.H.; Rodríguez-Soto, J.M.; Uribarri, J.; Díaz-Cisneros, F.J.; Cai, W.; Garay-Sevilla, M.E. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. Nutrition 2015, 31, 446–451. [Google Scholar] [CrossRef] [PubMed]
- Tantalaki, E.; Piperi, C.; Livadas, S.; Kollias, A.; Adamopoulos, C.; Koulouri, A.; Christakou, C.; Diamanti-Kandarakis, E. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones 2014, 13, 65–73. [Google Scholar] [CrossRef] [PubMed]
- Uribarri, J.; Peppa, M.; Cai, W.; Goldberg, T.; Lu, M.; He, C.; Vlassara, H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. JASN 2003, 14, 728–731. [Google Scholar] [CrossRef] [PubMed]
- de Courten, B.; de Courten, M.P.; Soldatos, G.; Dougherty, S.L.; Straznicky, N.; Schlaich, M.; Sourris, K.C.; Chand, V.; Scheijen, J.L.; Kingwell, B.A.; et al. Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: A double-blind, randomized, crossover trial. Am. J. Clin. Nutr. 2016, 103, 1426–1433. [Google Scholar] [CrossRef]
- Seiquer, I.; Rubio, L.A.; Peinado, M.J.; Delgado-Andrade, C.; Navarro, M.P. Maillard reaction products modulate gut microbiota composition in adolescents. Mol. Nutr. Food Res. 2014, 58, 1552–1560. [Google Scholar] [CrossRef]
- Seiquer, I.; Ruiz-Roca, B.; Mesías, M.; Muñoz-Hoyos, A.; Galdó, G.; Ochoa, J.J.; Navarro, M.P. The antioxidant effect of a diet rich in Maillard reaction products is attenuated after consumption by healthy male adolescents. In vitro and in vivo comparative study. J. Sci. Food Agric. 2008, 88, 1245–1252. [Google Scholar]
- Stirban, A.; Kotsi, P.; Franke, K.; Strijowski, U.; Cai, W.; Götting, C.; Tschoepe, D. Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins. Diabetes Care 2013, 36, 1278–1282. [Google Scholar] [CrossRef] [PubMed]
- Stirban, A.; Negrean, M.; Götting, C.; Uribarri, J.; Gawlowski, T.; Stratmann, B.; Kleesiek, K.; Koschinsky, T.; Vlassara, H.; Tschoepe, D. Dietary advanced glycation endproducts and oxidative stress: In vivo effects on endothelial function and adipokines. Ann. N. Y. Acad. Sci. 2008, 1126, 276–279. [Google Scholar] [CrossRef] [PubMed]
- Stirban, A.; Negrean, M.; Stratmann, B.; Götting, C.; Salomon, J.; Kleesiek, K.; Tschoepe, D. Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: An effect prevented by benfotiamine and cooking method. Diabetes Care 2007, 30, 2514–2516. [Google Scholar] [CrossRef]
- Goudarzi, R.; Sedaghat, M.; Hedayati, M.; Hekmatdoost, A.; Sohrab, G. Low advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Iranian patients with metabolic syndrome: A randomized clinical trial. J. Diabetes Metab. Disord. 2020, 19, 1129–1138. [Google Scholar] [CrossRef] [PubMed]
- Linkens, A.M.; Houben, A.J.; Niessen, P.M.; Wijckmans, N.E.; de Goei, E.E.; Van den Eynde, M.D.; Scheijen, J.L.; van den Waarenburg, M.P.; Mari, A.; Berendschot, T.T.; et al. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight 2022, 7, e156950. [Google Scholar] [CrossRef]
- Birlouez-Aragon, I.; Saavedra, G.; Tessier, F.J.; Galinier, A.; Ait-Ameur, L.; Lacoste, F.; Niamba, C.N.; Alt, N.; Somoza, V.; Lecerf, J.M. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am. J. Clin. Nutr. 2010, 91, 1220–1226. [Google Scholar] [CrossRef] [PubMed]
- Cordova, R.; Knaze, V.; Viallon, V.; Rust, P.; Schalkwijk, C.G.; Weiderpass, E.; Wagner, K.H.; Mayen-Chacon, A.L.; Aglago, E.K.; Dahm, C.C.; et al. Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults. Eur. J. Nutr. 2020, 59, 2893–2904. [Google Scholar] [CrossRef]
- Yacoub, R.; Nugent, M.; Cai, W.; Nadkarni, G.N.; Chaves, L.D.; Abyad, S.; Honan, A.M.; Thomas, S.A.; Zheng, W.; Valiyaparambil, S.A.; et al. Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLoS ONE 2017, 12, e0184789. [Google Scholar] [CrossRef] [PubMed]
- Sohouli, M.H.; Sharifi-Zahabi, E.; Lari, A.; Fatahi, S.; Shidfar, F. The impact of low advanced glycation end products diet on obesity and related hormones: A systematic review and meta-analysis. Sci. Rep. 2020, 10, 22194. [Google Scholar] [CrossRef]
- Nigro, C.; Raciti, G.A.; Leone, A.; Fleming, T.H.; Longo, M.; Prevenzano, I.; Fiory, F.; Mirra, P.; D’Esposito, V.; Ulianich, L.; et al. Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia 2014, 57, 1485–1494. [Google Scholar] [CrossRef]
- Nin, J.W.; Jorsal, A.; Ferreira, I.; Schalkwijk, C.G.; Prins, M.H.; Parving, H.H.; Tarnow, L.; Rossing, P.; Stehouwer, C.D. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care 2011, 34, 442–447. [Google Scholar] [CrossRef] [PubMed]
- Tikellis, C.; Pickering, R.J.; Tsorotes, D.; Huet, O.; Cooper, M.E.; Jandeleit-Dahm, K.; Thomas, M.C. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 2014, 63, 3915–3925. [Google Scholar] [CrossRef] [PubMed]
- Hanssen, N.M.; Beulens, J.W.; van Dieren, S.; Scheijen, J.L.; van der A, D.L.; Spijkerman, A.M.; van der Schouw, Y.T.; Stehouwer, C.D.; Schalkwijk, C.G. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: A case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015, 64, 257–265. [Google Scholar] [CrossRef] [PubMed]
- Maessen, D.E.; Hanssen, N.M.; Lips, M.A.; Scheijen, J.L.; Willems van Dijk, K.; Pijl, H.; Stehouwer, C.D.; Schalkwijk, C.G. Energy restriction and Roux-en-Y gastric bypass reduce postprandial α-dicarbonyl stress in obese women with type 2 diabetes. Diabetologia 2016, 59, 2013–2017. [Google Scholar] [CrossRef]
- Van den Eynde, M.D.G.; Kusters, Y.; Houben, A.; Scheijen, J.; van Duynhoven, J.; Fazelzadeh, P.; Joris, P.J.; Plat, J.; Mensink, R.P.; Hanssen, N.M.J.; et al. Diet-induced weight loss reduces postprandial dicarbonyl stress in abdominally obese men: Secondary analysis of a randomized controlled trial. Clin. Nutr. 2021, 40, 2654–2662. [Google Scholar] [CrossRef]
- Wautier, M.P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E685–E694. [Google Scholar] [CrossRef]
- Lee, H.W.; Gu, M.J.; Kim, Y.; Lee, J.Y.; Lee, S.; Choi, I.W.; Ha, S.K. Glyoxal-Lysine Dimer, an Advanced Glycation End Product, Induces Oxidative Damage and Inflammatory Response by Interacting with RAGE. Antioxidants 2021, 10, 1486. [Google Scholar] [CrossRef]
- Cepas, V.; Manig, F.; Mayo, J.C.; Hellwig, M.; Collotta, D.; Sanmartino, V.; Carrocera-Pumarino, R.; Collino, M.; Henle, T.; Sainz, R.M. In Vitro Evaluation of the Toxicological Profile and Oxidative Stress of Relevant Diet-Related Advanced Glycation End Products and Related 1,2-Dicarbonyls. Oxidative Med. Cell. Longev. 2021, 2021, 9912240. [Google Scholar] [CrossRef]
- Kong, X.; Lu, A.L.; Yao, X.M.; Hua, Q.; Li, X.Y.; Qin, L.; Zhang, H.M.; Meng, G.X.; Su, Q. Activation of NLRP3 Inflammasome by Advanced Glycation End Products Promotes Pancreatic Islet Damage. Oxidative Med. Cell. Longev. 2017, 2017, 9692546. [Google Scholar] [CrossRef]
- Son, S.; Hwang, I.; Han, S.H.; Shin, J.S.; Shin, O.S.; Yu, J.W. Advanced glycation end products impair NLRP3 inflammasome-mediated innate immune responses in macrophages. J. Biol. Chem. 2017, 292, 20437–20448. [Google Scholar] [CrossRef]
- Buetler, T.M.; Leclerc, E.; Baumeyer, A.; Latado, H.; Newell, J.; Adolfsson, O.; Parisod, V.; Richoz, J.; Maurer, S.; Foata, F.; et al. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol. Nutr. Food Res. 2008, 52, 370–378. [Google Scholar] [CrossRef] [PubMed]
- Reddy, S.; Bichler, J.; Wells-Knecht, K.J.; Thorpe, S.R.; Baynes, J.W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995, 34, 10872–10878. [Google Scholar] [CrossRef] [PubMed]
- Tessier, F.J.; Niquet-Léridon, C.; Jacolot, P.; Jouquand, C.; Genin, M.; Schmidt, A.M.; Grossin, N.; Boulanger, E. Quantitative assessment of organ distribution of dietary protein-bound (13) C-labeled N(ɛ) -carboxymethyllysine after a chronic oral exposure in mice. Mol. Nutr. Food Res. 2016, 60, 2446–2456. [Google Scholar] [CrossRef] [PubMed]
- Song, F.; Hurtado del Pozo, C.; Rosario, R.; Zou, Y.S.; Ananthakrishnan, R.; Xu, X.; Patel, P.R.; Benoit, V.M.; Yan, S.F.; Li, H.; et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 2014, 63, 1948–1965. [Google Scholar] [CrossRef] [PubMed]
- Gaens, K.H.; Goossens, G.H.; Niessen, P.M.; van Greevenbroek, M.M.; van der Kallen, C.J.; Niessen, H.W.; Rensen, S.S.; Buurman, W.A.; Greve, J.W.; Blaak, E.E.; et al. Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1199–1208. [Google Scholar] [CrossRef] [PubMed]
- Gaens, K.H.; Ferreira, I.; van de Waarenburg, M.P.; van Greevenbroek, M.M.; van der Kallen, C.J.; Dekker, J.M.; Nijpels, G.; Rensen, S.S.; Stehouwer, C.D.; Schalkwijk, C.G. Protein-Bound Plasma Nε-(Carboxymethyl)lysine Is Inversely Associated With Central Obesity and Inflammation and Significantly Explain a Part of the Central Obesity-Related Increase in Inflammation: The Hoorn and CODAM Studies. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 2707–2713. [Google Scholar] [CrossRef]
- Ruiz, H.H.; Nguyen, A.; Wang, C.; He, L.; Li, H.; Hallowell, P.; McNamara, C.; Schmidt, A.M. AGE/RAGE/DIAPH1 axis is associated with immunometabolic markers and risk of insulin resistance in subcutaneous but not omental adipose tissue in human obesity. Int. J. Obes. 2021, 45, 2083–2094. [Google Scholar] [CrossRef]
- Grossin, N.; Auger, F.; Niquet-Leridon, C.; Durieux, N.; Montaigne, D.; Schmidt, A.M.; Susen, S.; Jacolot, P.; Beuscart, J.B.; Tessier, F.J.; et al. Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol. Nutr. Food Res. 2015, 59, 927–938. [Google Scholar] [CrossRef]
- Aronson, D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 2003, 21, 3–12. [Google Scholar] [CrossRef]
- Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006, 114, 597–605. [Google Scholar] [CrossRef]
- Hegab, Z.; Gibbons, S.; Neyses, L.; Mamas, M.A. Role of advanced glycation end products in cardiovascular disease. World J. Cardiol. 2012, 4, 90–102. [Google Scholar] [CrossRef] [PubMed]
- Teissier, T.; Boulanger, É. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Biogerontology 2019, 20, 279–301. [Google Scholar] [CrossRef] [PubMed]
- Matsumoto, S.; Yoshida, T.; Murata, H.; Harada, S.; Fujita, N.; Nakamura, S.; Yamamoto, Y.; Watanabe, T.; Yonekura, H.; Yamamoto, H.; et al. Solution structure of the variable-type domain of the receptor for advanced glycation end products: New insight into AGE-RAGE interaction. Biochemistry 2008, 47, 12299–12311. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wang, H.; Piper, M.G.; McMaken, S.; Mo, X.; Opalek, J.; Schmidt, A.M.; Marsh, C.B. sRAGE induces human monocyte survival and differentiation. J. Immunol. 2010, 185, 1822–1835. [Google Scholar] [CrossRef]
- Pollreisz, A.; Hudson, B.I.; Chang, J.S.; Qu, W.; Cheng, B.; Papapanou, P.N.; Schmidt, A.M.; Lalla, E. Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells. Atherosclerosis 2010, 212, 451–456. [Google Scholar] [CrossRef]
- Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic, S.; Golenbock, D.; Sirois, C.; et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8, 487–496. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Liang, C.; Liu, X.; Liao, B.; Pan, X.; Ren, Y.; Fan, M.; Li, M.; He, Z.; Wu, J.; et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010, 208, 34–42. [Google Scholar] [CrossRef]
- Nah, S.S.; Choi, I.Y.; Yoo, B.; Kim, Y.G.; Moon, H.B.; Lee, C.K. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett. 2007, 581, 1928–1932. [Google Scholar] [CrossRef]
- Zhu, P.; Ren, M.; Yang, C.; Hu, Y.X.; Ran, J.M.; Yan, L. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp. Dermatol. 2012, 21, 123–129. [Google Scholar] [CrossRef]
- Bierhaus, A.; Humpert, P.M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D.M.; Nawroth, P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005, 83, 876–886. [Google Scholar] [CrossRef]
- Kierdorf, K.; Fritz, G. RAGE regulation and signaling in inflammation and beyond. J. Leukoc. Biol. 2013, 94, 55–68. [Google Scholar] [CrossRef] [PubMed]
- Gao, Z.Q.; Yang, C.; Wang, Y.Y.; Wang, P.; Chen, H.L.; Zhang, X.D.; Liu, R.; Li, W.L.; Qin, X.J.; Liang, X.; et al. RAGE upregulation and nuclear factor-kappaB activation associated with ageing rat cardiomyocyte dysfunction. Gen. Physiol. Biophys. 2008, 27, 152–158. [Google Scholar] [PubMed]
- D’Adamo, E.; Giannini, C.; Chiavaroli, V.; de Giorgis, T.; Verrotti, A.; Chiarelli, F.; Mohn, A. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? Antioxid. Redox Signal. 2011, 14, 1167–1172. [Google Scholar] [CrossRef]
- Schmidt, A.M.; Stern, D. Atherosclerosis and diabetes: The RAGE connection. Curr. Atheroscler. Rep. 2000, 2, 430–436. [Google Scholar] [CrossRef] [PubMed]
- Yoon, S.J.; Park, S.; Park, C.; Chang, W.; Cho, D.K.; Ko, Y.G.; Choi, D.; Kwon, H.M.; Jang, Y.; Chung, N. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Coron. Artery Dis. 2012, 23, 85–90. [Google Scholar] [CrossRef]
- Koyama, H.; Nishizawa, Y. AGEs/RAGE in CKD: Irreversible metabolic memory road toward CVD? Eur. J. Clin. Investig. 2010, 40, 623–635. [Google Scholar] [CrossRef]
- Guclu, M.; Ali, A.; Eroglu, D.U.; Büyükuysal, S.O.; Cander, S.; Ocak, N. Serum Levels of sRAGE Are Associated with Body Measurements, but Not Glycemic Parameters in Patients with Prediabetes. Metab. Syndr. Relat. Disord. 2016, 14, 33–39. [Google Scholar] [CrossRef]
- Dozio, E.; Briganti, S.; Delnevo, A.; Vianello, E.; Ermetici, F.; Secchi, F.; Sardanelli, F.; Morricone, L.; Malavazos, A.E.; Corsi Romanelli, M.M. Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women. Eur. J. Nutr. 2017, 56, 2557–2564. [Google Scholar] [CrossRef]
- Rowisha, M.; El-Batch, M.; El Shikh, T.; El Melegy, S.; Aly, H. Soluble receptor and gene polymorphism for AGE: Relationship with obesity and cardiovascular risks. Pediatr. Res. 2016, 80, 67–71. [Google Scholar] [CrossRef]
- Miranda, E.R.; Somal, V.S.; Mey, J.T.; Blackburn, B.K.; Wang, E.; Farabi, S.; Karstoft, K.; Fealy, C.E.; Kashyap, S.; Kirwan, J.P.; et al. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2017, 313, E631–E640. [Google Scholar] [CrossRef]
- Zaki, M.; Kamal, S.; Kholousi, S.; El-Bassyouni, H.T.; Yousef, W.; Reyad, H.; Mohamed, R.; Basha, W.A. Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women. EXCLI J. 2017, 16, 973–980. [Google Scholar] [CrossRef] [PubMed]
- Steenbeke, M.; De Bruyne, S.; De Buyzere, M.; Lapauw, B.; Speeckaert, R.; Petrovic, M.; Delanghe, J.R.; Speeckaert, M.M. The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome. Crit. Rev. Clin. Lab. Sci. 2021, 58, 113–130. [Google Scholar] [CrossRef] [PubMed]
- Park, L.; Raman, K.G.; Lee, K.J.; Lu, Y.; Ferran, L.J., Jr.; Chow, W.S.; Stern, D.; Schmidt, A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4, 1025–1031. [Google Scholar] [CrossRef] [PubMed]
- Wautier, J.L.; Zoukourian, C.; Chappey, O.; Wautier, M.P.; Guillausseau, P.J.; Cao, R.; Hori, O.; Stern, D.; Schmidt, A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Investig. 1996, 97, 238–243. [Google Scholar] [CrossRef]
- Bucciarelli, L.G.; Wendt, T.; Qu, W.; Lu, Y.; Lalla, E.; Rong, L.L.; Goova, M.T.; Moser, B.; Kislinger, T.; Lee, D.C.; et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106, 2827–2835. [Google Scholar] [CrossRef]
- Ha, C.H.; Kim, S.; Chung, J.; An, S.H.; Park, S.; Choi, D.; Kwon, K. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis. Int. J. Mol. Med. 2013, 32, 373–380. [Google Scholar] [CrossRef]
- Rodríguez-Mortera, R.; Luevano-Contreras, C.; Solorio-Meza, S.; Gómez-Ojeda, A.; Caccavello, R.; Bains, Y.; Gugliucci, A.; Garay-Sevilla, M.E. Soluble Receptor for Advanced Glycation End Products and Its Correlation with Vascular Damage in Adolescents with Obesity. Horm. Res. Paediatr. 2019, 92, 28–35. [Google Scholar] [CrossRef]
- Saremi, A.; Howell, S.; Schwenke, D.C.; Bahn, G.; Beisswenger, P.J.; Reaven, P.D. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study. Diabetes Care 2017, 40, 591–598. [Google Scholar] [CrossRef]
- Rabbani, N.; Xue, M.; Thornalley, P.J. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj. J. 2016, 33, 513–525. [Google Scholar] [CrossRef]
- Gautieri, A.; Passini, F.S.; Silván, U.; Guizar-Sicairos, M.; Carimati, G.; Volpi, P.; Moretti, M.; Schoenhuber, H.; Redaelli, A.; Berli, M.; et al. Advanced glycation end-products: Mechanics of aged collagen from molecule to tissue. Matrix Biol. J. Int. Soc. Matrix Biol. 2017, 59, 95–108. [Google Scholar] [CrossRef]
- Bucala, R.; Makita, Z.; Vega, G.; Grundy, S.; Koschinsky, T.; Cerami, A.; Vlassara, H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA 1994, 91, 9441–9445. [Google Scholar] [CrossRef] [PubMed]
- Posch, K.; Simecek, S.; Wascher, T.C.; Jürgens, G.; Baumgartner-Parzer, S.; Kostner, G.M.; Graier, W.F. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells. Diabetes 1999, 48, 1331–1337. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, A.M.; Hasu, M.; Popov, D.; Zhang, J.H.; Chen, J.; Yan, S.D.; Brett, J.; Cao, R.; Kuwabara, K.; Costache, G.; et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. USA 1994, 91, 8807–8811. [Google Scholar] [CrossRef] [PubMed]
- Maasen, K.; Eussen, S.; Dagnelie, P.C.; Houben, A.; Webers, C.A.B.; Schram, M.T.; Berendschot, T.; Stehouwer, C.D.A.; Opperhuizen, A.; van Greevenbroek, M.M.J.; et al. Habitual intake of dietary methylglyoxal is associated with less low-grade inflammation: The Maastricht Study. Am. J. Clin. Nutr. 2022, 116, 1715–1728. [Google Scholar] [CrossRef]
- Linkens, A.M.A.; Houben, A.; Kroon, A.A.; Schram, M.T.; Berendschot, T.; Webers, C.A.B.; van Greevenbroek, M.; Henry, R.M.A.; de Galan, B.; Stehouwer, C.D.A.; et al. Habitual intake of dietary advanced glycation end products is not associated with generalized microvascular function-the Maastricht Study. Am. J. Clin. Nutr. 2022, 115, 444–455. [Google Scholar] [CrossRef]
- Linkens, A.M.; Eussen, S.J.; Houben, A.J.; Kroon, A.A.; Schram, M.T.; Reesink, K.D.; Dagnelie, P.C.; Henry, R.M.; van Greevenbroek, M.; Wesselius, A.; et al. Habitual Intake of Dietary Advanced Glycation End Products Is Not Associated with Arterial Stiffness of the Aorta and Carotid Artery in Adults: The Maastricht Study. J. Nutr. 2021, 151, 1886–1893. [Google Scholar] [CrossRef]
- Hold, G.L. Western lifestyle: A ‘master’ manipulator of the intestinal microbiota? Gut 2014, 63, 5–6. [Google Scholar] [CrossRef]
- Agus, A.; Denizot, J.; Thévenot, J.; Martinez-Medina, M.; Massier, S.; Sauvanet, P.; Bernalier-Donadille, A.; Denis, S.; Hofman, P.; Bonnet, R.; et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci. Rep. 2016, 6, 19032. [Google Scholar] [CrossRef]
- Martinez, K.B.; Leone, V.; Chang, E.B. Western diets, gut dysbiosis, and metabolic diseases: Are they linked? Gut Microbes 2017, 8, 130–142. [Google Scholar] [CrossRef]
- Linkens, A.M.A.; van Best, N.; Niessen, P.M.; Wijckmans, N.E.G.; de Goei, E.E.C.; Scheijen, J.; van Dongen, M.; van Gool, C.; de Vos, W.M.; Houben, A.; et al. A 4-Week Diet Low or High in Advanced Glycation Endproducts Has Limited Impact on Gut Microbial Composition in Abdominally Obese Individuals: The deAGEing Trial. Int. J. Mol. Sci. 2022, 23, 5328. [Google Scholar] [CrossRef]
- Flint, H.J.; Bayer, E.A.; Rincon, M.T.; Lamed, R.; White, B.A. Polysaccharide utilization by gut bacteria: Potential for new insights from genomic analysis. Nat. Rev. Microbiol. 2008, 6, 121–131. [Google Scholar] [CrossRef] [PubMed]
- Moschen, A.R.; Gerner, R.R.; Wang, J.; Klepsch, V.; Adolph, T.E.; Reider, S.J.; Hackl, H.; Pfister, A.; Schilling, J.; Moser, P.L.; et al. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe 2016, 19, 455–469. [Google Scholar] [CrossRef] [PubMed]
- Maynard, J.D.; Rohrscheib, M.; Way, J.F.; Nguyen, C.M.; Ediger, M.N. Noninvasive type 2 diabetes screening: Superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007, 30, 1120–1124. [Google Scholar] [CrossRef]
- Fokkens, B.T.; van Waateringe, R.P.; Mulder, D.J.; Wolffenbuttel, B.H.R.; Smit, A.J. Skin autofluorescence improves the Finnish Diabetes Risk Score in the detection of diabetes in a large population-based cohort: The LifeLines Cohort Study. Diabetes Metab. 2018, 44, 424–430. [Google Scholar] [CrossRef] [PubMed]
- de Vos, L.C.; Mulder, D.J.; Smit, A.J.; Dullaart, R.P.; Kleefstra, N.; Lijfering, W.M.; Kamphuisen, P.W.; Zeebregts, C.J.; Lefrandt, J.D. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 933–938. [Google Scholar] [CrossRef]
- Meerwaldt, R.; Lutgers, H.L.; Links, T.P.; Graaff, R.; Baynes, J.W.; Gans, R.O.; Smit, A.J. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30, 107–112. [Google Scholar] [CrossRef] [PubMed]
- Lutgers, H.L.; Gerrits, E.G.; Graaff, R.; Links, T.P.; Sluiter, W.J.; Gans, R.O.; Bilo, H.J.; Smit, A.J. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52, 789–797. [Google Scholar] [CrossRef]
- Fraser, S.D.; Roderick, P.J.; McIntyre, N.J.; Harris, S.; McIntyre, C.W.; Fluck, R.J.; Taal, M.W. Skin autofluorescence and all-cause mortality in stage 3 CKD. Clin. J. Am. Soc. Nephrol. CJASN 2014, 9, 1361–1368. [Google Scholar] [CrossRef]
- Siriopol, D.; Hogas, S.; Veisa, G.; Mititiuc, I.; Volovat, C.; Apetrii, M.; Onofriescu, M.; Busila, I.; Oleniuc, M.; Covic, A. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. Int. Urol. Nephrol. 2015, 47, 563–569. [Google Scholar] [CrossRef]
- Shardlow, A.; McIntyre, N.J.; Kolhe, N.V.; Nellums, L.B.; Fluck, R.J.; McIntyre, C.W.; Taal, M.W. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. PLoS Med. 2020, 17, e1003163. [Google Scholar] [CrossRef]
- Arsov, S.; Trajceska, L.; van Oeveren, W.; Smit, A.J.; Dzekova, P.; Stegmayr, B.; Sikole, A.; Rakhorst, G.; Graaff, R. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif. Organs 2013, 37, E114–E122. [Google Scholar] [CrossRef] [PubMed]
- Furuya, F.; Shimura, H.; Takahashi, K.; Akiyama, D.; Motosugi, A.; Ikegishi, Y.; Haraguchi, K.; Kobayashi, T. Skin autofluorescence is a predictor of cardiovascular disease in chronic kidney disease patients. Ther. Apher. Dial. 2015, 19, 40–44. [Google Scholar] [CrossRef] [PubMed]
- Kimura, H.; Tanaka, K.; Kanno, M.; Watanabe, K.; Hayashi, Y.; Asahi, K.; Suzuki, H.; Sato, K.; Sakaue, M.; Terawaki, H.; et al. Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis. Ther. Apher. Dial. 2014, 18, 461–467. [Google Scholar] [CrossRef] [PubMed]
- Vélayoudom-Céphise, F.L.; Rajaobelina, K.; Helmer, C.; Nov, S.; Pupier, E.; Blanco, L.; Hugo, M.; Farges, B.; Astrugue, C.; Gin, H.; et al. Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: A longitudinal study. Cardiovasc. Diabetol. 2016, 15, 127. [Google Scholar] [CrossRef]
- Blanc-Bisson, C.; Velayoudom-Cephise, F.L.; Cougnard-Gregoire, A.; Helmer, C.; Rajaobelina, K.; Delcourt, C.; Alexandre, L.; Blanco, L.; Mohammedi, K.; Monlun, M.; et al. Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: A 7-year follow-up study. Cardiovasc. Diabetol. 2018, 17, 82. [Google Scholar] [CrossRef]
- van Waateringe, R.P.; Fokkens, B.T.; Slagter, S.N.; van der Klauw, M.M.; van Vliet-Ostaptchouk, J.V.; Graaff, R.; Paterson, A.D.; Smit, A.J.; Lutgers, H.L.; Wolffenbuttel, B.H.R. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia 2019, 62, 269–280. [Google Scholar] [CrossRef]
- Raposeiras-Roubín, S.; Rodiño-Janeiro, B.K.; Paradela-Dobarro, B.; Grigorian-Shamagian, L.; García-Acuña, J.M.; Aguiar-Souto, P.; Jacquet-Hervet, M.; Reino-Maceiras, M.V.; González-Juanatey, J.R.; Álvarez, E. Fluorescent advanced glycation end products and their soluble receptor: The birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. PLoS ONE 2013, 8, e74302. [Google Scholar] [CrossRef]
- Raposeiras-Roubín, S.; Rodino-Janeiro, B.K.; Paradela-Dobarro, B.; Almansour, H.; Grigorian-Shamagian, L.; Reino-Maceiras, M.V.; García-Acuña, J.M.; González-Juanatey, J.R.; Álvarez, E. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome. Biomark. Med. 2015, 9, 209–216. [Google Scholar] [CrossRef]
- Jensen, L.J.; Lindberg, S.; Hoffmann, S.; Iversen, A.Z.; Pedersen, S.H.; Møgelvang, R.; Galatius, S.; Flyvbjerg, A.; Jensen, J.S.; Bjerre, M. Dynamic changes in sRAGE levels and relationship with cardiac function in STEMI patients. Clin. Biochem. 2015, 48, 297–301. [Google Scholar] [CrossRef]
- Choi, L.S.; Ahmed, K.; Kim, Y.S.; Yim, J.E. Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. Heliyon 2022, 8, e09571. [Google Scholar] [CrossRef]
- den Engelsen, C.; van den Donk, M.; Gorter, K.J.; Salomé, P.L.; Rutten, G.E. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Derm.-Endocrinol. 2012, 4, 33–38. [Google Scholar] [CrossRef] [PubMed]
- van Waateringe, R.P.; Slagter, S.N.; van Beek, A.P.; van der Klauw, M.M.; van Vliet-Ostaptchouk, J.V.; Graaff, R.; Paterson, A.D.; Lutgers, H.L.; Wolffenbuttel, B.H.R. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol. Metab. Syndr. 2017, 9, 42. [Google Scholar] [CrossRef] [PubMed]
- Yamagishi, S.; Fukami, K.; Matsui, T. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Int. J. Cardiol. 2015, 185, 263–268. [Google Scholar] [CrossRef] [PubMed]
- Da Moura Semedo, C.; Webb, M.; Waller, H.; Khunti, K.; Davies, M. Skin autofluorescence, a non-invasive marker of advanced glycation end products: Clinical relevance and limitations. Postgrad. Med. J. 2017, 93, 289–294. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, Y. Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies. Nutrients 2023, 15, 2002. https://doi.org/10.3390/nu15082002
Kim Y. Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies. Nutrients. 2023; 15(8):2002. https://doi.org/10.3390/nu15082002
Chicago/Turabian StyleKim, Yoona. 2023. "Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies" Nutrients 15, no. 8: 2002. https://doi.org/10.3390/nu15082002